Evinova’s Pharma Push
Evinova expanded its AI-native clinical platform through strategic collaborations with Astellas, AstraZeneca and Bristol Myers Squibb — signaling multi-pharma validation of AI-enabled trial operations reported. Those partnerships suggest interoperable analytics platforms can move from niche pilots to standardized clinical delivery.
Each partner “opted in to share operational data” with Evinova, a move the company said enables cross‑company benchmarks and model training on pooled trial operations data. evinova.com Bristol Myers Squibb signed to deploy Evinova’s Cost Optimizer module, announced in a Feb 9, 2026 press release that ties the module to commercialization of AI‑driven trial cost forecasting. markets.financialcontent.com Applied Clinical Trials reported the platform offers end‑to‑end development support with multi‑agent AI and cited projected 5–7% trial cost savings from improved protocol design and fewer amendments. appliedclinicaltrialsonline.com AstraZeneca originally launched Evinova as a separate health‑tech business on Nov 20, 2023 and retains long‑term backing, while Evinova announced a Feb 26, 2026 Citeline integration to surface integrated data intelligence for smarter protocol design. astrazeneca.com
